Net Profits? Search Engine Placements, E-Mail Ads Touted By DTC Marketers
This article was originally published in The Gray Sheet
Executive Summary
Gaining visibility on Internet search engines and using e-mail as a marketing tool are two direct-to-consumer tactics that should be considered by med tech companies with limited budgets, participants suggested at a Sept. 30-Oct. 1 Center for Business Intelligence marketing conference
You may also be interested in...
Endocare Prostate Cancer Device Reaches Consumers Via Cable TV
Relatively inexpensive rates for late-night cable ads can lend a national dimension to DTC device campaigns without a large financial investment, Endocare VP-Marketing Paul LaPine told participants at CBI's "Direct-to-Consumer Strategies for Medical Devices" conference in Chicago Sept. 30-Oct. 1
Bear Stearns Healthcare Conference In Brief
HeartMate II trial: Thoratec will submit a protocol to FDA for its second-generation destination therapy left-ventricular assist device clinical trial "fairly soon," President & CEO Keith Grossman told Bear Stearns Healthcare Conference attendees in New York Sept. 14. The study likely will include two arms: a 50-100 patient, non-randomized, non-controlled bridge-to-transplant arm and a 150-200 patient destination therapy arm with two-year follow-up, randomizing HeartMate II to HeartMate. The trial will support a PMA filing for the bridge indication and subsequent PMA supplement for destination therapy (1"The Gray Sheet" Dec. 8, 2003, p. 26)....LVAD reimbursement: The number of centers qualified by CMS to receive reimbursement for destination therapy should increase from 68 to about 100 in the next few years, Thoratec's Grossman predicts. CMS is creating a "more formal certification program that probably within the next six to 12 months will be in place" and should allow centers to get certified in a more fluid way...
Device DTC Guidances Aim To Hone Enforcement, Stimulate Patient Education
FDA's draft guidances for consumer advertising establish explicit standards to which the agency will hold medical device manufacturers accountable, according to Commissioner Mark McClellan